KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.Orphanet J Rare DisPMID 39574155PMC115837402024-Nov-210.98未发现恶性肿瘤人群证据。待处理
Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018).J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39186709无 PMCID2024-Nov-201.00命中用户提供的消化道肿瘤阳性参考集。无 KM 图
Extent of Lymphadenectomy for Surgical Management of Right-Sided Colon Cancer: The Randomized Phase III RELARC Trial.J Clin OncolPMID 39190853无 PMCID2024-Nov-200.93干预为非药物单独策略,未满足药物干预要求。待处理
Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study.Acta Derm VenereolPMID 39565228PMC116006072024-Nov-200.98未发现恶性肿瘤人群证据。待处理
Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury: The TRAIN Randomized Clinical Trial.JAMAPMID 39382241PMC115815742024-Nov-190.98未发现恶性肿瘤人群证据。待处理
Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine.J Clin Endocrinol MetabPMID 38412282无 PMCID2024-Nov-180.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial.BMJPMID 39557487PMC115710492024-Nov-180.98未发现恶性肿瘤人群证据。待处理
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39550172无 PMCID2024-Nov-160.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-Like Reactions During Treatment of Latent Tuberculosis Infection.J Infect DisPMID 38640958PMC114893172024-Nov-150.98未发现恶性肿瘤人群证据。待处理
Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults.J Infect DisPMID 38889247PMC115662302024-Nov-150.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines.Aesthet Surg JPMID 38913088PMC115660372024-Nov-150.98未发现恶性肿瘤人群证据。待处理
Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial.J Infect DisPMID 39028902PMC115662252024-Nov-150.98未发现恶性肿瘤人群证据。待处理
SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback.J Infect DisPMID 39036987PMC115662362024-Nov-150.98未发现恶性肿瘤人群证据。待处理
Efficacy of attractive targeted sugar bait stations against malaria in Western Province Zambia: epidemiological findings from a two-arm cluster randomized phase III trial.Malar JPMID 39548456PMC115665502024-Nov-150.98未发现恶性肿瘤人群证据。待处理
Preoperative Chemoradiotherapy for Resectable Gastric Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39282905无 PMCID2024-Nov-141.00命中用户提供的消化道肿瘤阳性参考集。无 KM 图
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39282910无 PMCID2024-Nov-140.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial.Signal Transduct Target TherPMID 39532849PMC115579262024-Nov-130.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.J Patient Rep OutcomesPMID 39535661PMC115612192024-Nov-130.98未发现恶性肿瘤人群证据。待处理
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial.RMD OpenPMID 39537558PMC115753452024-Nov-130.90The study is a randomized phase III trial with a drug intervention (adalimumab) and reports original results, but it is not an oncology study (rheumatoid arthritis) and does not have a time-to-event efficacy endpoint. The primary outcomes are categorical (remission/low disease activity) and continuous (CRP levels), not survival or progression metrics.待处理
Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial.J Am Coll CardiolPMID 39387764无 PMCID2024-Nov-120.98未发现恶性肿瘤人群证据。待处理
Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia: The Randomized, Phase 3 REMAIN-2 Trial.J Am Coll CardiolPMID 39505412无 PMCID2024-Nov-120.98未发现恶性肿瘤人群证据。待处理
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial.Nat CommunPMID 39532861PMC115578892024-Nov-120.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study.Arthritis Res TherPMID 39533349PMC115560752024-Nov-120.90The study is a randomized, Phase III clinical trial of a drug (upadacitinib) with original results, but it is not an oncology study (it investigates ankylosing spondylitis, a rheumatologic condition). Therefore, it fails the fundamental oncology criterion required for this cohort.待处理
Effect of Esophageal Dilation History on Efficacy Outcomes in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension.Am J GastroenterolPMID 39631042PMC122083882024-Nov-120.98未发现恶性肿瘤人群证据。待处理
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma).J Clin OncolPMID 39270145无 PMCID2024-Nov-100.90The study is an eligible Phase III randomized human oncology trial with primary time-to-event efficacy endpoints (EFS, OS). However, the intervention compares two types of transplantation (autologous vs. allogeneic hematopoietic stem cell transplantation), not a drug-containing intervention. Therefore, it does not meet the inclusion criteria for a drug intervention.待处理
Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS.Lupus Sci MedPMID 39521453PMC115520232024-Nov-090.98未发现恶性肿瘤人群证据。待处理
Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder: a pooled post hoc analysis of two randomized phase 3 clinical studies.SleepPMID 38644625PMC115436232024-Nov-080.98未发现恶性肿瘤人群证据。待处理
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 38828984无 PMCID2024-Nov-070.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 38899716无 PMCID2024-Nov-070.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy.J Am Coll CardiolPMID 39217556无 PMCID2024-Nov-050.98未发现恶性肿瘤人群证据。待处理
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy.J Am Coll CardiolPMID 39217563无 PMCID2024-Nov-050.98未发现恶性肿瘤人群证据。待处理
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.J Am Coll CardiolPMID 39217569PMC119755292024-Nov-050.98未发现恶性肿瘤人群证据。待处理
Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial.JAMAPMID 39264623PMC113937532024-Nov-050.98未发现恶性肿瘤人群证据。待处理
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.J Am Coll CardiolPMID 39352339无 PMCID2024-Nov-050.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Weekly Calcifediol Formulations (75 and 100 µg) in Subjects with Vitamin D Deficiency: A Phase II/III Randomised Trial.NutrientsPMID 39599585PMC115975092024-Nov-050.98未发现恶性肿瘤人群证据。待处理
Impact of Upadacitinib Induction and Maintenance Therapy on Health-related Quality of Life, Fatigue, and Work Productivity in Patients with Moderately-to-severely Active Crohn's Disease.J Crohns ColitisPMID 38835235PMC115326152024-Nov-040.98未发现恶性肿瘤人群证据。待处理
Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin Therapy.J Crohns ColitisPMID 38836628PMC115326132024-Nov-040.90The record describes a Phase 3, randomized trial in ulcerative colitis (not oncology) with drug interventions (infliximab, etrolizumab) and original results on clinical remission. However, it does not include a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier analysis, or HR) as required for inclusion in the cohort.待处理
Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme.J Crohns ColitisPMID 38869019PMC115326122024-Nov-040.98未发现恶性肿瘤人群证据。待处理
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.J Crohns ColitisPMID 38877972PMC115326102024-Nov-040.98未发现恶性肿瘤人群证据。待处理
Concordance of patient- and clinician-reported outcomes of acute radiation dermatitis in breast cancer.Support Care CancerPMID 39495339无 PMCID2024-Nov-040.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Recombinant Human Thyrotropin Plus Radioactive Iodine Among Patients With Thyroid Cancer: A Noninferiority Randomized Clinical Trial.JAMA Netw OpenPMID 39509132PMC115444862024-Nov-040.95The study meets most criteria (oncology, human, randomized, Phase III, original report, drug intervention) but fails the critical requirement of having a primary or key secondary time-to-event efficacy endpoint. The primary endpoint is a noninferiority comparison of success rates (binary outcome) at 6-8 months, not a survival or progression-free survival analysis with time-to-event methodology.待处理
Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema.Transl Vis Sci TechnolPMID 39535745PMC115629742024-Nov-040.98未发现恶性肿瘤人群证据。待处理
Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials.Rheumatology (Oxford)PMID 38331400PMC115341172024-Nov-010.98未发现恶性肿瘤人群证据。待处理
Prehospital tranexamic acid is associated with a survival benefit without an increase in complications: Results of two harmonized randomized clinical trials.J Trauma Acute Care SurgPMID 38523128PMC114225172024-Nov-010.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial.J Atheroscler ThrombPMID 38616112PMC115377842024-Nov-010.98未发现恶性肿瘤人群证据。待处理
Application of Recombinant Human Superoxide Dismutase in Radical Concurrent Chemoradiotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Acute Rectal Injury: A Multicenter, Randomized, Open-label, Prospective Trial.Int J Radiat Oncol Biol PhysPMID 38705489无 PMCID2024-Nov-010.45Trial meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result. However, it is excluded because the primary and secondary endpoints are focused on the incidence and duration of radiation-induced acute rectal injury (diarrhea) and mucosal damage, which are safety/toxicity endpoints, not a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR reporting.待处理
Laparoscopic versus open pancreatoduodenectomy for periampullary tumors: a randomized clinical trial.Int J SurgPMID 39172725PMC115730482024-Nov-010.93干预为非药物单独策略,未满足药物干预要求。待处理
Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.JAMA Intern MedPMID 39226070PMC113726532024-Nov-010.98未发现恶性肿瘤人群证据。待处理
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial.JAMA CardiolPMID 39230885PMC113755262024-Nov-010.98未发现恶性肿瘤人群证据。待处理
Semen analysis and reproductive hormones in boys with classical Hodgkin lymphoma treated according to the EuroNet-PHL-C2 protocol.Hum ReprodPMID 39256932PMC115326072024-Nov-010.45The record is an add-on study to a randomized phase-3 trial evaluating a drug-containing chemotherapy regimen for Hodgkin lymphoma in boys. However, it is not an original result report of the trial's primary efficacy endpoint (e.g., OS, PFS). Instead, it is a secondary analysis focusing on reproductive toxicity (semen parameters, hormones), which is a safety/quality-of-life-related outcome, not a primary time-to-event efficacy endpoint required for inclusion.待处理